$25.93
8.49% yesterday
Nasdaq, Oct 15, 10:16 pm CET
ISIN
US45826J1051
Symbol
NTLA

Intellia Therapeutics, Inc. Stock price

$25.93
+14.36 124.11% 1M
+18.57 252.31% 6M
+14.27 122.38% YTD
+6.41 32.84% 1Y
-28.64 52.48% 3Y
+1.68 6.93% 5Y
+3.83 17.33% 10Y
+3.83 17.33% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+2.03 8.49%
ISIN
US45826J1051
Symbol
NTLA
Industry

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.3b
Net debt
positive
Cash
$459.7m
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
52.7 | 44.0
EV/Sales
44.0 | 36.8
EV/FCF
negative
P/B
3.9
Financial Health
Equity Ratio
73.2%
Return on Equity
-59.5%
ROCE
-63.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$52.9m | $63.2m
EBITDA
$-501.9m | $-456.0m
EBIT
$-512.0m | $-461.7m
Net Income
$-480.2m | $-441.8m
Free Cash Flow
$-421.8m
Growth (TTM | estimate)
Revenue
-37.2% | 9.2%
EBITDA
43.6% | 13.0%
EBIT
43.1% | 13.6%
Net Income
44.0% | 14.9%
Free Cash Flow
-10.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-949.5% | -721.4%
EBIT
-968.7%
Net
-908.5% | -699.0%
Free Cash Flow
-798.0%
More
EPS
$-4.6
FCF per Share
$-4.0
Short interest
31.4%
Employees
403
Rev per Employee
$140.0k
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Intellia Therapeutics, Inc. forecast:

24x Buy
77%
6x Hold
19%
1x Sell
3%

Analyst Opinions

31 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
77%
Hold
19%
Sell
3%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
53 53
37% 37%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 119 119
43% 43%
225%
- Research and Development Expense 446 446
42% 42%
843%
-502 -502
44% 44%
-949%
- Depreciation and Amortization 10 10
3% 3%
19%
EBIT (Operating Income) EBIT -512 -512
43% 43%
-969%
Net Profit -480 -480
44% 44%
-908%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
The Motley Fool
4 days ago
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced.
Positive
The Motley Fool
9 days ago
Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by Wall Street analysts, there's still plenty of upside left for the stock.
Neutral
GlobeNewsWire
13 days ago
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today